E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036909 |
E.1.2 | Term | Prostate cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the anti-tumour effect after treatment with 0.45mg/kg Irofulven in combination prednisolone in patients who progressed on AR-targeted therapy (abiraterone acetate, enzalutamide or investigational AR-targeted agent) and docetaxel-pretreated metastatic castration-resistant prostate cancer and that were selected by the Irofulven DRP. |
|
E.2.2 | Secondary objectives of the trial |
• To determine the safety profile of Irofulven combined with prednisone in castration resistant metastatic prostate cancer patients, pre-treated with docetaxel and AR-targeted therapy
• To assess duration of response (DOR)
• To assess radiologic PFS (rPFS)
• To assess overall survival (OS)
• To assess PSA response ≥ 50% (all patients)
• To assess PSA response ≥ 90% (all patients)
• To assess time to PSA progression
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to participate in this study the subjects must meet all of the following inclusion criteria:
1. Have a histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate (carcinomas with pure small-cell histology or pure high grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)
2. Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL. For patients currently being treated with luteinizing hormone–releasing hormone (LHRH) agonists, i.e., patients who have not undergone an orchiectomy, therapy must be continued throughout the study
3. Have evidence of disease progression after prior therapy for mCRPC:
a.Disease progression after treatment with at least 1 but no more than 2 prior next-generation AR-targeted therapies (abiraterone acetate, enzalutamide, or investigational AR-targeted agent) for metastatic prostate cancer (treatment with the older anti-androgen therapies such as bicalutamide, flutamide, and nilutamide are not counted toward this limit), AND
b. Disease progression after treatment with docetaxel for metastatic Prostate cancer. Prior Docetaxel therapy administered for hormone-sensitive disease is permitted and is not counted toward this limit. Disease progression after initiation of most recent therapy is based on any of the following criteria:
• Rise in PSA: a minimum of 2 consecutive rising levels, with an interval of ≥ 1 week between each determination. The most recent screening measurement must have been ≥ 1 ng/mL
• Transaxial imaging: new or progressive soft tissue masses on CT or MRI scans as defined by RECIST 1.1
• Radionuclide bone scan: at least 2 new metastatic lesions
4. Signed informed consent obtained prior to initiation of any study-specific procedures or treatment
5. Age ≥ 18 years
6. Life expectancy ≥ 3 months
7. Performance status 0 - 1
8. Drug response predictor (DRPTM) in the upper likelihood of response (DRP value is available via the screening procedure performed by Medical Prognosis Institute)
9. Adequate organ functions
a. Hematological: absolute neutrophil count (ANC) >1.5 x 109/L, platelet count >100 x 109/L, hemoglobin > 6,2 mmol/L
b. Hepatic: Bilirubin within normal range, aspartate transaminase (AST) and alanine transaminase (ALT) <2.5 UNL, albumin > 25 g/L
c. Renal: creatinine clearance >30 mL/min (calculated according to the Cockcroft and Gault method)
10. Recovered to grade 0 or 1 from any toxic effects of prior chemotherapy, radiotherapy
|
|
E.4 | Principal exclusion criteria |
In order to participate in the study subjects must not meet any of the following exclusion criteria:
1. Prior external beam radiation therapy to >25% of the bone marrow
2. Contraindication to the use of prednisolone (e.g. uncontrolled diabetes mellitus)
3. Prior treatment with Irofulven.
4. Ongoing treatment with a corticosteroid at a prednisolone-equivalent dose > 10 mg/day
5. More than 1 prior treatment with either 153Sm or 89Sr, or radioisotope treatment or treatment with bisphosphonate agents or antibody treatment i.e., denosumab within 2 months prior to initiation of treatment with IMP. Pre-existing treatment with bisphosphonate agents or denosumab is to be continued during the study
6. Initiation of treatment with bisphosphonate agents or antibody treatment i.e., denosumab, within 4 weeks of study start. Pre-existing treatment with bisphosphonate agents or denosumab is to be continued during the study
7. Treatment with coumarin derivatives and/or phenytoin most be discontinued and coagulation parameters most be within the normal range before treatment with Irofulven
8. History of significant gastric or small bowel resection, malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that may prevent compliance with oral drug administration
9. Presence of any serious concomitant systemic disorders and/or psychiatric condition incompatible with the study (at the investigator’s discretion)
10. History of retinopathy
11. Presence of any active infection (at the investigator’s discretion).
12. CNS disease including epilepsy or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Anti-Tumour effect of Irofulven with prednisolone on clinical benefit rate defined as complete response, partial response or stable disease > 9 weeks according to RECIST 1.1 for patients with measurable disease and defined as stable disease > 9 weeks according to PCWG3 for bone metastases.
• All patients who receive at least 2 treatment cycles (4 daily treatments with Irofulven) will be considered evaluable for response.
• Patients discontinuing early due to disease progression will also be evaluable for response
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After at least 2 treatment cycles. |
|
E.5.2 | Secondary end point(s) |
• Duration of response (DOR) is defined as Time from documentation of tumour response to disease progression.
• Radiologic progression free survival (rPFS), rPFS was defined as ≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 9 weeks after enrolment, and/or progression in nodes or viscera on cross-sectional imaging, or death.
• Overall survival defined as time from enrolment until death from any cause.
• PSA response defined as ≥ 50% decline in PSA compared to baseline in all patients according to PCWG3.
• PSA response defined as ≥ 90% decline in PSA compared to baseline in all patients according to PCWG3.
• Time to PSA progression will be is defined in accordance with PCWG3.
Safety variables:
• Incidence and severity (NCI-CTCAE version 4.03) of clinical adverse events and laboratory abnormalities; occurrence of serious adverse events (SAEs) and treatment discontinuation for adverse events, measurement of vital signs and ECG. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit (LPLV) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |